Dexmedetomidine, Ketamine and Magnesium Sulphate in Caudal Block for Hypospadias Repair

NCT ID: NCT05837000

Last Updated: 2023-06-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-15

Study Completion Date

2024-10-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Caudal epidural block is a rapid, reliable, and safe technique that can be used with general anesthesia for intraoperative and postoperative analgesia in pediatric patients Ketamine is a selective antagonist of N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preemptive Analgesia Dexmedetomidine Ketamine Magnesium Sulphate Hypospadias Pediatrics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dexmedetomidine

0.5 ml/kg bupivacaine 0.25% + 1μg/kg dexmedetomidine caudally

Group Type EXPERIMENTAL

Dexmedetomidine

Intervention Type DRUG

Patient will receive 0.5 ml/kg bupivacaine 0.25% + 1μg/kg dexmedetomidine caudally

Ketamine

0.5 ml/kg bupivacaine 0.25% + 1μg/kg dexmedetomidine caudally

Group Type EXPERIMENTAL

Ketamine

Intervention Type DRUG

Patient will receive 0.5ml/kg bupivacaine 0.25% + 0.5mg/kg ketamine caudally

Magnesium sulphate

0.5ml/kg bupivacaine 0.25% + 1ml volume containing 50mg of magnesium caudally.

Group Type EXPERIMENTAL

Magnesium sulphate

Intervention Type DRUG

Patient will receive 0.5ml/kg bupivacaine 0.25% + 1ml volume containing 50mg of magnesium caudally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexmedetomidine

Patient will receive 0.5 ml/kg bupivacaine 0.25% + 1μg/kg dexmedetomidine caudally

Intervention Type DRUG

Ketamine

Patient will receive 0.5ml/kg bupivacaine 0.25% + 0.5mg/kg ketamine caudally

Intervention Type DRUG

Magnesium sulphate

Patient will receive 0.5ml/kg bupivacaine 0.25% + 1ml volume containing 50mg of magnesium caudally.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 1-7 years
* American Society of Anesthesiologists (ASA) classification I and II, undergoing hypospadias repair.

Exclusion Criteria

* Developmental delay
* Psychological or neurological disorders
* Difficult airway
* Hyperactive airway disease or children in whom caudal block was contraindicated (e.g., infection at the site of block, bleeding disorder, or abnormalities of the sacrum).
Minimum Eligible Age

1 Year

Maximum Eligible Age

7 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Kafrelsheikh University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Gamal Hendawy Shams

Lecturer

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kafrelsheikh University

Role: PRINCIPAL_INVESTIGATOR

Research ethics committee - Kafrelsheikh University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Karelsheikh University Hospital

Kafr ash Shaykh, Karelsheikh, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Gamal MD Hendawy Shams, MD

Role: CONTACT

00201095927971

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Gamal H Shams, MD

Role: primary

00201095927971

Study Documents

Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.

Document Type: Study Protocol

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MKSU 51- 2 - 16

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Regional Anaesthesia
NCT06055101 COMPLETED NA